Jerini AG Announces Research Collaboration Between Jerini Ophthalmic and University College London Institute of Ophthalmology Investigating New Treatments for AMD

BERLIN, Dec. 7, 2007 (PRIME NEWSWIRE) -- Jerini AG (Frankfurt:JI4) announced today that Jerini Ophthalmic, Inc., its wholly-owned U.S. subsidiary, signed a research collaboration agreement with University College London (UCL) Institute of Ophthalmology to investigate the pathobiology of AMD (age-related macular degeneration). The collaboration will explore the novel signaling pathways targeted by two of Jerini Ophthalmic's leading drug candidates: JSM 6427, an integrin antagonist, and JPE 1375, an inhibitor of the complement cascade. Under the terms of the agreement, Jerini Ophthalmic will finance full-time equivalents (FTE) and research costs over three years at the UCL Institute of Ophthalmology and has certain exclusive rights over the intellectual property generated through the collaboration.

Back to news